Published in Biotech Law Weekly, January 21st, 2005
The assets to be sold by Cygnus to Animas include substantially all of Cygnus' intellectual property rights, fixed assets, supplier, manufacturing and license agreements, inventory, and tangible personal property.
Assets excluded from the acquisition include Cygnus' cash and cash equivalents, accounts receivable, and its arbitration claim against Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.